<DOC>
	<DOCNO>NCT00978016</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety arbaclofen placarbil ( XP19986 ) versus placebo adjunctive therapy subject troublesome GERD symptom despite therapy approve dos Proton Pump Inhibitor ( PPI ) .</brief_summary>
	<brief_title>A Study Evaluate Efficacy Safety Arbaclofen Placarbil ( XP19986 ) Adjunctive Therapy Subjects With Gastroesophageal Reflux Disease ( GERD )</brief_title>
	<detailed_description />
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Rabeprazole</mesh_term>
	<mesh_term>Lansoprazole</mesh_term>
	<mesh_term>Dexlansoprazole</mesh_term>
	<mesh_term>Pantoprazole</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Proton Pump Inhibitors</mesh_term>
	<mesh_term>Arbaclofen placarbil</mesh_term>
	<mesh_term>Baclofen</mesh_term>
	<criteria>1. confirmed diagnosis GERD gastroenterologist 2. minimum 3 month GERD symptom prior screen . 3. currently take FDA approve dose PPI therapy symptomatic GERD least 4 week prior screen 4. experienced partial relief GERD symptom receive approve dose regimen PPI therapy 5. experience GERD symptom , define heartburn ( without regurgitation GERD symptom ) â‰¥ 3 day week prior screen 1. evidence erosive esophagitis erosive gastritis upper gastrointestinal endoscopy screen 2. experienced GERD symptom improvement adequate course PPI treatment ( least 2 week ) 3. unstable severe medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>GERD</keyword>
</DOC>